Sobi Reports Positive Q1 2025 Financial Results Amid Market Challenges and Growth in Haematology

Sobi Reports Positive Q1 2025 Financial Results



On April 29, 2025, Swedish Orphan Biovitrum AB, commonly known as Sobi®, unveiled its financial report for the first quarter of 2025, revealing promising growth in its revenue streams, particularly within the haematology segment. The report highlights a total revenue increase of 3% compared to the same quarter last year, amounting to SEK 6,465 million while maintaining similar growth at constant exchange rates.

Haematology Segment Performance



A standout performance was noted in the haematology division, which saw an impressive revenue surge of 13% at constant exchange rates. Key drivers of this growth included strong sales from several flagship products. Altuvoct, introduced recently, contributed SEK 455 million in sales, marking a significant entry into the market. Furthermore, sales from Doptelet reached SEK 1,129 million, a notable jump from SEK 756 million in the previous year. Aspaveli and Empaveli also performed robustly, generating SEK 333 million, despite Vonjo's slightly decreased sales at SEK 306 million.

Challenges in Immunology



Conversely, the immunology sector faced a downturn, with revenues decreasing by 21% at constant exchange rates, totaling SEK 1,526 million. This decline was largely attributed to dramatically lower sales of Synagis, down to SEK 21 million from SEK 520 million, along with a decrease in Beyfortus royalties. Fortunately, the sales of Gamifant and Kineret provided some offset, generating SEK 582 million and SEK 735 million respectively, but overall performance in this segment clearly fell short of expectations.

Strategic Portfolio Growth



Sobi’s strategic portfolio, which includes various medications such as Altuvoct, Aspaveli/Empaveli, and others, showcased remarkable growth of 46% at constant exchange rates, achieving revenue of SEK 3,255 million. This highlights Sobi’s commitment to expanding its reach and enhancing the value provided through its specialized treatments for rare diseases.

Financial Deep Dive



Details from the adjusted EBITA margin indicate a slight contraction to 36%, down from 37%, though the EBITA itself was SEK 2,260 million, maintaining a margin of 35% consistent with the previous year. Earnings per share (EPS) demonstrated a positive trajectory with pre-dilution EPS increasing to SEK 2.55 compared to SEK 2.35 in Q1 2024. After dilution adjustments, EPS rose to SEK 2.52 from SEK 2.33.

The cash flow from operations also showed stability, amounting to SEK 2,295 million, slightly above last year's figure.

2025 Outlook



Looking ahead, Sobi maintains its forecast for the full year 2025. Revenue growth is expected to be in the high single digits at constant exchange rates, accompanied by an adjusted EBITA margin projected to settle in the mid-30s percentage range of total revenue.

Sobi continues to position itself as a leader in the biopharma sector, committed to unlocking potential breakthrough innovations aimed at transforming everyday life for individuals grappling with rare diseases.

Investors and analysts interested in further insights can tune into a conference call scheduled for later the same day, providing a comprehensive overview of these results and an interactive Q&A session.

For ongoing updates and more detailed annual figures, stakeholders are encouraged to visit sobi.com.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.